For the quarter ending 2025-09-30, IMCR made $103,693K in revenue. -$3,569K in net income. Net profit margin of -3.44%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 103,693 | 97,964 | 93,881 | 80,248 |
| Cost of revenue from sale of therapies | 513 | 1,040 | 831 | 448 |
| Research and development expense | 70,572 | 69,008 | 56,468 | 52,770 |
| Selling, general and administrative expense | 39,779 | 42,791 | 40,198 | 35,532 |
| Loss from operations | -7,171 | -14,875 | -3,616 | -8,502 |
| Interest income | 4,123 | 4,271 | 4,176 | 5,960 |
| Interest expense | 3,043 | 3,045 | 3,025 | 4,290 |
| Foreign currency gain | 1,333 | -738 | 3,080 | 3,963 |
| Other income, net | 5,062 | 4,693 | 5,469 | 8,962 |
| Net income (loss) before income taxes | 304 | -9,694 | 6,084 | 6,093 |
| Income tax (expense) benefit | 481 | 606 | 1,061 | -2,643 |
| Net (loss) income | -177 | -10,300 | 5,023 | 8,736 |
| Exchange differences on translation of foreign operations | -3,392 | 6,476 | 673 | 3,247 |
| Total comprehensive (loss) income | -3,569 | -3,824 | 5,696 | 11,983 |
| Basic net (loss) income per share (in usd per share) | 0 | -0.2 | 0.1 | 0.17 |
| Basic weighted-average number of shares outstanding (in shares) | 50,403,717 | 50,294,205 | 50,086,684 | 50,021,939 |
| Diluted net (loss) income per share (in usd per share) | 0 | -0.2 | 0.1 | 0.17 |
| Diluted weighted-average number of shares outstanding (in shares) | 50,403,717 | 50,294,205 | 51,949,798 | 52,808,434 |
Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR)